

EXPRESS MAIL MAILING LABEL NO. EV192307163US

PATENT

Attorney Docket No. INL-044C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rosén *et al.*

SERIAL NUMBER: 10/050,441 GROUP NUMBER: 1651

FILING DATE: January 16, 2002 EXAMINER: Ralph J. Gitomer

TITLE: IN VITRO METHODS FOR SCREENING FOR BLOOD COAGULATION DISORDERS USING METAL IONS

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the publication listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. A copy of the publication is enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
 - the requisite Statement is below, OR
 - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

(3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**

the requisite Statement is below, **AND**

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or


2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: November 7, 2003
Reg. No. 43,153

Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100

2707752



Diana M. Steel
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



EXPRESS MAIL MAILING LABEL NO. EV192307163US

FORM PTO - 1449

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: INL-044CI

APPLICANTS: Rosén *et al.*

SERIAL NO.: 10/050,441

FILING DATE: January 16, 2002

RECEIVED
NOV 14 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A7	2003/0199014 A1	10/23/03				

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

2707763

EXAMINER	DATE CONSIDERED
----------	-----------------

EXPRESS MAIL MAILING LABEL
NO. EV192307163US

COPY

EXPRESS MAIL MAILING LABEL NO.: E1917371535US

<p>FORM PTO - 1449</p> <p>INFORMATION DISCLOSURE STATEMENT</p> <p style="text-align: right;">100-2000</p> <p style="text-align: center;"><i>NOV 07 2003</i></p> <p style="text-align: center;">JC95</p> <p style="text-align: center;">PATENT & TRADEMARK OFFICE</p>	<p>EXPRESS MAIL MAILING LABEL NO.: EL917371535US</p> <p>ATTORNEY DOCKET NO.: INL-044C1</p> <p>APPLICANTS: Rosén et al.</p> <p>SERIAL NO.: Not yet assigned 10/050,441</p> <p>FILING DATE: Herewith 11/16/2002</p> <p>GROUP: Not yet assigned 1651</p>
--	---

U.S. PATENT DOCUMENTS


SEARCHED DOCUMENTS							
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RG	A1	5,001,069	03/19/91	Bartl et al.	436	86	RECEIVED NOV 1 1991 TECH CENTER 16
	A2	5,055,412	10/08/91	Proksch	436	69	
	A3	5,439,802	08/08/95	Rosén	453	13	
	A4	5,637,452	06/10/97	Speck	435	4	
✓	A5	5,637,492	06/10/97	Dawson et al.	435	217	

FOREIGN PATENT DOCUMENTS

SEARCHED DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
Ree	B1	WO 93/10262	05/27/93	PCT					Y
RCG	B2	WO 9941615	08/19/99	PCT					Y

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)	
<i>RCA</i>	C1	Bernardo et al.: Surface-independent Acceleration of Factor XII Activation by Zinc Ions, <i>J. Biol. Chem.</i> 268(17):12468-12476 (1993).
	C2	Butenas et al.: Cooperative Interaction of Divalent Metal Ions, Substrate, and Tissue Factor with Factor VIIa, <i>J. Biol. Chem.</i> 33:3449-3456 (1994).
	C3	Gable et al.: Protac, A Commercially Available Protein C Activator From the Venom of <i>Agkistrodon Contortrix Contortrix</i> , Can Activate Factor V and Factor VIII, <i>Thrombosis Research</i> 86(1): 79-84 (1997).
	C4	Heeb et al.: Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin, <i>J. Biol. Chem.</i> 266(26):17606-17612 (1991).
	C5	Liebman et al.: The Factor IX Phospholipid-binding Site Is Required for Calcium-dependent Activation of Factor IX by Factor Xia, <i>J. Biol. Chem.</i> 262(16):7605-7612 (1987).
<i>C</i>	C6	Pedersen et al.: Inhibition of Recombinant Human Blood Coagulation Factor VIIa Amidolytic and Proteolytic Activity by Zinc Ions, <i>Thrombosis and Haemostasis</i> 65(5):528-534 (1991).

FORM PTO - 1449			ATTORNEY DOCKET NO.: INL-044C1
INFORMATION DISCLOSURE STATEMENT			APPLICANTS: Rosén et al.
			SERIAL NO.: Not yet assigned
			FILING DATE: Herewith
			GROUP: Not yet assigned
RLG	C8	Shore et al.: Regulation of the Tertiary Structure and Function of Coagulation Factor IX by Magnesium (II) Ions*, <i>J. Biol. Chem.</i> 270(24):14325-14331 (1995).	
RLG	C8	Shore et al.: Acceleration of Surface-Dependent Autocatalytic Activation of Blood Coagulation Factor XII by Divalent Metal Ions, <i>J. Biol. Chem.</i> 26: 2250-2258 (1987).	
EXAMINER R GUTOMEN		DATE CONSIDERED 12/13/02	
BRESNAHA4643/51.2259847			